B+
Bull case
20%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
GANX
Gain TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-05
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.4
Score
AI commentary
Company and SEC Q2 materials are operationally constructive, including IND authorization and planned clinical milestones, but coverage is sparse. No usable social aggregate, analyst revisions, or reliable post-print market-reaction data is available. The negative deterministic signal and binary clinical profile support cautious monitoring rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-09-05
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-04eventRexaceract Phase 2 initiationHigh impact
FDA authorization of the rexaceract IND positions Gain to begin a Phase 2 Parkinson’s study, which management expects in Q3 2026. Timely initiation would support the development thesis; delay would pressure the stock [#SEC-8K-2026-08-11].
2027-09-05catalystPhase 1b extension final dataHigh impact
Final results from the nine-month Phase 1b extension are expected in Q4 2026, with presentation planned at the International Congress of Parkinson’s Disease and Movement Disorders in October. Results could validate or weaken the disease-modifying thesis [#PR-EARNINGS-2026-08-11].
2027-09-05catalystGT-04686 indication selectionHigh impact
Gain expects to identify an initial target indication for GT-04686 in Q4 2026 as the program advances toward IND-enabling studies. This offers pipeline-expansion potential but remains an early-stage, lower-confidence catalyst [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-05 • Updated nightlySource: Internal modelMethodology